The agency is establishing a network of care centers to expand access to regenerative medicine beyond regions served by major ...

NEW YORK – Azalea Therapeutics launched on Tuesday, having raised $82 million in seed and Series A financing to develop in vivo genetic medicines for cancer and autoimmune conditions using its ...

The firm had decreased Q3 sales for precision oncology drugs including Ibrance, Tukysa, and Bosulif, but sales increased for ...

The company will focus on advancing a program in hematological malignancies and plans to launch a registrational trial in 2026.

The firm is now offering combined ex vivo drug sensitivity and genomic testing to cancer patients outside the clinical trial setting.

The firm is refocusing its resources on a KAT6A degrader for estrogen receptor-positive breast cancer and a previously undisclosed JAK2 Inhibitor.

The firm's stock tumbled on the news, dropping from $24.45 per share at market close Monday to $15.24 per share when the market opened Tuesday.

Based on strong preclinical data on HMPL-A251 in HER2-positive tumor cell lines, the firm wants to take the therapy into clinical trials by year end.

The start of the trial marks an expansion of the firm's oncology pipeline, and the firm hopes mRNA-2808 will be the first of many T-cell engagers in its portfolio.

The firm, which had planned to submit a BLA in 2026 for AMT-130, described the FDA's latest feedback as a "drastic change" and "unexpected." ...

The study will test the antibody-drug conjugate in combination with Keytruda in patients with HER2-overexpressing metastatic non-small cell lung cancer.

The influential oncology guidelines body revised guidelines with a nod to the FDA's explicit recommendation for testing in Xeloda's label.